论文部分内容阅读
目的:观察重组人粒细胞集落刺激因子(rhG-CSF)对化疗后骨髓抑制患者T淋巴细胞组成的影响。方法:化疗后出现Ⅱ°骨髓抑制的患者,给予皮下注射rhG-CSF150g,连续3d,用药前及用药后第3天用流式细胞仪检测外周血T淋巴细胞组成的变化。结果:流式细胞术分析发现,用药前CD4+T淋巴细胞占外周血CD3+T淋巴细胞比例为(52.96±8.45)%,用药后为(54.15±7.55)%,差异无统计学意义(P>0.05);用药前CD8+T淋巴细胞占外周血CD3+T淋巴细胞比例为(36.96±9.62)%,用药后为(34.56±8.32)%,差异无统计学意义(P>0.05);用药前CD4+CD25+T淋巴细胞占外周血CD4+T淋巴细胞比例为(4.56±1.32)%,用药后为(6.94±1.72)%,差异有统计学意义(P=0.000)。结论:rhG-CSF对化疗后骨髓抑制患者CD4+T淋巴细胞、CD8+T淋巴细胞在CD3+T淋巴细胞中的百分比无明显影响;但增加了CD4+CD25+T淋巴细胞在CD4+T淋巴细胞中的百分比。
Objective: To observe the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the T lymphocyte in patients with myelosuppression after chemotherapy. Methods: Patients with Ⅱ ° myelosuppression after chemotherapy were given 150g of rhG-CSF subcutaneously for 3 days. The changes of T lymphocytes in peripheral blood were detected by flow cytometry before and 3 days after treatment. Results: The results of flow cytometry showed that the percentage of CD4 + T lymphocytes in peripheral blood was (52.96 ± 8.45)% before treatment and (54.15 ± 7.55)% after treatment, the difference was not statistically significant (P > 0.05). Before treatment, the percentage of CD8 + T lymphocytes in peripheral blood was (36.96 ± 9.62)% and (34.56 ± 8.32)%, respectively, with no significant difference (P> 0.05) The proportion of CD4 + T lymphocytes in peripheral CD4 + T lymphocytes was (4.56 ± 1.32)% before treatment and (6.94 ± 1.72)% after treatment. The difference was statistically significant (P = 0.000). Conclusion: There is no significant effect of rhG-CSF on the percentage of CD4 + T lymphocytes and CD8 + T lymphocytes in CD3 + T lymphocytes in patients with myelosuppression after chemotherapy. However, the percentage of CD4 + T lymphocytes in CD4 + T lymphocytes increased Percentage in cells.